Our systematic approach to therapeutics discovery starts with the development of a patient biobank and validation of a disease-specific, in vitro deep phenotype, which serve as the inputs into our scaled drug discovery engine. Each of our disease programs, from discovery through clinical trials, is continually informed by this rigorous scientific foundation and therefore has a greater chance of truly moving the needle in curing brain disease.

Cures, not correlations.